## Pharmacy Services
San Francisco Health Plan Pharmacy & Therapeutics Committee

**Meeting called by:** Lisa Ghotbi, Pharm. D

**Meeting Objective:** Vote on proposed formulary and prior authorization (PA) criteria changes

**Type of meeting:** Quarterly

### Attendees:

**Voting Members:**
- Lisa Ghotbi, Pharm. D (SFHP Director of Pharmacy)
- James Glauber, MD (SFHP Chief Medical Officer) *Off-site vote*
- Ted Li, MD
- Ronald Ruggiero, Pharm. D
- Maria Lopez, Pharm. D
- Linda Truong, Pharm. D
- Robert (Brad) Williams, MD

**Others in Attendance:**
- Kaitlin Hawkins, Pharm. D (SFHP Pharmacist)
- Ralph Crowder, R.Ph (SFHP Pharmacist)
- Jessica Shost, Pharm. D (SFHP Pharmacist)
- Kent Truong, Pharm. D (SFHP Resident Pharmacist)
- Betty Liang (SFHP Pharmacy Student)
- Jenna Heath, Pharm. D (PerformRx Pharmacist)

### Members Absent:
- Shawn Houghtaling, Pharm. D
- Nicholas Jew, MD
- Jamie Ruiz, MD
- Steven Wozniak, MD
- Joseph Pace, MD

### Meeting Materials:

- Summary of all approved changes are posted under “Materials” section at [https://www.sfhp.org/files/meeting_agendas/PnT_Committee/PnTMaterialsJanuary2019.pdf](https://www.sfhp.org/files/meeting_agendas/PnT_Committee/PnTMaterialsJanuary2019.pdf)
- SFHP formulary is located at [https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/](https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/)
- SFHP prior authorization criteria are located at [https://www.sfhp.org/files/providers/formulary/SFHP_Prior_Auth_Criteria.pdf](https://www.sfhp.org/files/providers/formulary/SFHP_Prior_Auth_Criteria.pdf)

### Topics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
</table>
| 1. Call to Order | Lisa Ghotbi | The meeting was called to order at 7:45 am.  
- Conflict of interest check  
- Agenda overview | Conflict of Interest checked and instructions given. Introduction agenda topics done. |
| 2. Informational Updates | Lisa Ghotbi | Topics:  
| 3. Review and Approval of October 17, 2018 P&T minutes *(pp.5 - 15 of January 16, 2019 P&T Packet)* | Lisa Ghotbi | The committee approved the minutes as presented. | VOTE: Review and Approval of October 17, 2018 P&T Minutes  
Approved recommendations as presented.  
**Motion:** Ronald Ruggiero, Pharm. D  
**Vote:** Unanimous approval (7/7) |
**Adjoin to Closed Session**

Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Discussion and Recommendation for Change to SFHP Formulary and Prior Authorization Criteria for Select Drug Classes.</td>
<td>Kaitlin Hawkins Kent Truong</td>
<td>The following drug classes were reviewed for pertinent literature (including meta-analyses and pivotal clinical trials), guideline updates, and drug additions to or removals from market since last class review. Major recommendations included the following: <strong>Formulary Recommendations:</strong> (Medi-Cal, HealthyKids HMO, HealthyWorkers HMO)  - None <strong>Prior Authorization (PA) Criteria Recommendations:</strong>  - None <strong>Drug Utilization Review (DUR) Recommendations:</strong>  - None</td>
<td>VOTE: <strong>Formulary Maintenance Items:</strong> Approved recommendations as presented.</td>
</tr>
<tr>
<td><strong>Multiple Sclerosis Class Review</strong> Motion: Ronald Ruggiero, Pharm. D Vote: Unanimous approval (7/7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. <strong>Formulary Maintenance Items:</strong> Neurology: Parkinson’s Disease  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Neurology: Parkinson’s Disease  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Formulary Recommendations: (HealthyKids HMO) Remove amantadine from formulary T3-F/PA <strong>PA Criteria Recommendations:</strong>  - None <strong>DUR Recommendations:</strong>  - None</td>
<td>VOTE: <strong>Formulary Maintenance Items:</strong> Approved recommendations as presented.</td>
</tr>
<tr>
<td><strong>Parkinson’s Disease Class Review</strong> Motion: Ronald Ruggiero, Pharm. D Vote: Unanimous approval (7/7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. <strong>Formulary Maintenance Items:</strong> Neurology: Alzheimer’s Disease and Dementia  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Neurology: Alzheimer’s Disease and Dementia  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Formulary Recommendations: (Medi-Cal, HealthyKids HMO, HealthyWorkers HMO &amp; Healthy San Francisco)  - None <strong>PA Criteria Recommendations:</strong>  - None <strong>DUR Recommendations:</strong>  - None</td>
<td>VOTE: <strong>Formulary Maintenance Items:</strong> Approved recommendations as presented.</td>
</tr>
<tr>
<td><strong>Alzheimer’s Disease and Dementia Class Review</strong> Motion: Ronald Ruggiero, Pharm. D Vote: Unanimous approval (7/7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. <strong>Formulary Maintenance Items:</strong> Endocrinology: Lipodystrophy disorders  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Endocrinology: Lipodystrophy disorders  (pp.16 - 30 of January 2019 P&amp;T Packet)</td>
<td>Formulary Recommendations: (Medi-Cal, HealthyKids HMO, HealthyWorkers HMO &amp; Healthy San Francisco)  - None <strong>PA Criteria Recommendations:</strong>  - None <strong>DUR Recommendations:</strong>  - None</td>
<td>VOTE: <strong>Formulary Maintenance Items:</strong> Approved recommendations as presented.</td>
</tr>
<tr>
<td><strong>Lipodystrophy disorders Class Review</strong> Motion: Ronald Ruggiero, Pharm. D Vote: Unanimous approval (7/7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. <strong>Formulary Maintenance Items:</strong> Psychiatry: Opioid, Nicotine &amp;</td>
<td>Psychiatry: Opioid, Nicotine &amp;</td>
<td>Formulary Recommendations: (Medi-Cal, HealthyKids HMO, HealthyWorkers HMO &amp;</td>
<td>VOTE: <strong>Formulary Maintenance Items:</strong></td>
</tr>
<tr>
<td>Topic</td>
<td>Brought By</td>
<td>Discussion</td>
<td>Action</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>------------</td>
<td>--------</td>
</tr>
</tbody>
</table>
| Alcohol Dependence Disorders  
(pp.16 - 30 of January 2019 P&T Packet) | PA Criteria Recommendations:  
None  
DUR Recommendations:  
None  
Committee Discussion:  
The committee had no comments or questions. | Approved recommendations as presented.  
**Opioid, Nicotine & Alcohol Dependence Disorders Class Review**  
Motion: Ronald Ruggiero, Pharm. D  
Vote: Unanimous approval (7/7) |
| Neurology:  
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists  
(pp.31 - 43 of January 2019 P&T Packet) | The plan presented class reviews & monograph with recommendations for Neurology medications.  
Major recommendations included the following:  
**Formulary Recommendations:**  
(Medi-Cal, Healthy Kids HMO & Healthy Workers HMO)  
- Add Emgality™ to formulary tier 3 as the preferred CGRP RA and require prior authorization to ensure appropriate diagnosis and use of preferred alternatives  
- Remove Aimovig™ from formulary due to preferred alternative Emgality™ and grandfather current users  
**PA Criteria Recommendations:**  
- Update Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists criteria to reflect formulary changes above  
**DUR Recommendations:**  
None  
Committee Discussion:  
The committee had no comments or questions. | VOTE:  
Neurology:  
Approved recommendations as presented.  
**Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists Class Review**  
Motion: Robert (Brad) Williams, MD  
Vote: Unanimous approval (7/7) |
| Neurology  
Epidiolex (cannabidiol) Monograph  
(pp.44 - 50 of January 2019 P&T Packet) | Formulary Recommendations:  
(Medi-Cal, Healthy Kids HMO & Healthy Workers HMO)  
- Keep Epidiolex® non-formulary at this time  
**PA Criteria Recommendations:**  
None  
**DUR Recommendations:**  
None  
Committee Discussion:  
The committee had no comments or questions. | VOTE:  
Neurology:  
Approved recommendations as presented.  
**Epidiolex (cannabidiol) Monograph**  
Motion: Robert (Brad) Williams, MD  
Vote: Unanimous approval (7/7) |
<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
</table>
| **Endocrinology**<br>Growth Hormone Disorders Class Review<br>(pp.51 - 67 of January 2019 P&T Packet) | Kaitlin Hawkins | The plan presented class reviews and recommendations for Endocrinology medications. Major recommendations included the following<br><br>**Formulary Recommendations:**<br>(Medi-Cal, Healthy Kids HMO & Healthy Workers HMO)<br>• Add Zomacton® to formulary tier 4, preferred for its labeled indications<br>• Remove Serostim® and Zorbtive® from formulary due to lack of utilization and no clear place in therapy<br>• Remove non-preferred formulations of growth hormone from formulary due to preferred alternatives available for other indications: Genotropin®, Humatrope®, Omnitrope®, Saizen®<br>• Remove Incrlex® from formulary due to lack utilization and lack of criteria<br>• Add octreotide 50mcg/mL, 100mcg/mL, and 500mcg/mL vial to formulary due to comparative cost-effectiveness<br>• Remove Somatuline® Depot and Sandostatin® LAR Depot from formulary as these should be administered by a HCP available through the medical benefit<br><br>**Prior Authorization Criteria Recommendations:**<br>• Update Somatropin (Growth Hormone) criteria to reflect formulary changes above, to streamline requirements, and to remove indications for non-formulary products with limited/no place in therapy<br>• Update Octreotide and Somavert® criteria to reflect formulary changes above<br><br>**DUR Recommendations:**<br>• None<br><br>**Committee Discussion:**<br>The committee had a discussion and determined to keep HIV/AIDS wasting syndrome on criteria as a covered diagnosis.<br><br>VOTE: Endocrinology<br>Approved recommendations as presented with the exception of keeping HIV/AIDS wasting syndrome on criteria as a covered diagnosis.<br><br>*Growth Hormone Disorders Class Review*<br><br>Motion: Ronald Ruggiero, Pharm. D<br>Vote: Unanimous approval (7/7)
| **Androgens Class Review**<br>(pp.68 – 81 of January 2019 P&T Packet) | Kaitlin Hawkins | **Formulary Recommendations:**<br>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco):<br>• None<br><br>**PA Criteria Recommendations:**<br>• Remove specific criteria for testosterone (Axiron®) solution pump due to comparable cost-effectiveness with other non-preferred options<br><br>**DUR Recommendations:**<br>• None<br><br>**Committee Discussion:**<br>The committee had a discussion regarding testosterone propionate on formulary and all transdermal being on Tier 1. It was determined that research will be done and a follow-up will occur.<br><br>VOTE: Endocrinology<br>Approve recommendations as presented.<br><br>*Androgens Class Review*<br><br>Motion: Ronald Ruggiero, Pharm. D<br>Vote: Unanimous approval (7/7)
<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. <strong>Pulmonology</strong>&lt;br&gt;Cystic Fibrosis Class Review&lt;br&gt;(pp. 82 - 94 of January 2019 P&amp;T Packet)</td>
<td>Kaitlin Hawkins</td>
<td>The plan presented a class review and recommendations for Pulmonology medications. Major recommendations included the following: <strong>Formulary Recommendations:</strong> (Medi-Cal, Healthy Kids HMO Healthy Workers HMO and Healthy San Francisco): - Remove Bethkis® (tobramycin) 300mg/4mL and tobramycin 300mg/5mL (Kitabis Pak®) from formulary due to lack of utilization and cost-effective alternative available <strong>PA Criteria Recommendations:</strong> - Update Cystic Fibrosis criteria based on formulary changes above, and to allow Kalydeco® (ivacaftor) use in newly indicated age range <strong>DUR Recommendations:</strong> - None <strong>Committee Discussion:</strong> The committee had no comments or questions.</td>
<td><strong>VOTE:</strong>&lt;br&gt;Pulmonology&lt;br&gt;Approve recommendations as presented.&lt;br&gt;Cystic Fibrosis Class Review&lt;br&gt;Motion: Ted Li, MD&lt;br&gt;Vote: Unanimous approval (7/7)</td>
</tr>
<tr>
<td>12. <strong>Supplements</strong>&lt;br&gt;Electrolytes, Vitamins and Minerals Abbreviated Review&lt;br&gt;(pp.95 - 112 of January 2019 P&amp;T Packet)</td>
<td>Kaitlin Hawkins</td>
<td>The plan presented a class review and recommendations for Supplemental medications. Major recommendations included the following: <strong>Formulary Recommendations:</strong> (Medi-Cal, Healthy Kids HMO Healthy Workers HMO and Healthy San Francisco): - Add prenatal vitamins to formulary as a class to reduce barriers to use  - Remove all quantity limits  - Consider dollar limit per prescription based on further analysis to prevent fraud/waste/abuse - Add thiamine mononitrate (B1) 100mg tab to formulary based on rejected claims and cost-effectiveness - Remove PA requirement from calcitriol 1mcg/mL oral solution and maintain on formulary tier 1, with age limit to allow appropriate pediatric use - Remove quantity limits from the following due to lack of abuse potential:  - calcium phos/vit D3 (Risacal-D®) 105mg-120u tab  - b complex/folic acid/c (Nephrovite®) 0.8mg tab - Add age limits to the following medications to allow appropriate pediatric use:  - ergocalciferol (vit D2) 8,000u/mL PO drops (OTC)  - Tri-Vi-Sol® 750u-35mg-400u/mL PO drops</td>
<td><strong>VOTE:</strong>&lt;br&gt;Supplements&lt;br&gt;Approve recommendations as presented.&lt;br&gt;Electrolytes, Vitamins and Minerals Abbreviated Review&lt;br&gt;Motion: Ronald Ruggiero, Pharm. D&lt;br&gt;Vote: Unanimous approval (7/7)</td>
</tr>
<tr>
<td>Topic</td>
<td>Brought By</td>
<td>Discussion</td>
<td>Action</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>------------</td>
<td>--------</td>
</tr>
<tr>
<td><strong>Cardiology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Heart Failure & Angina Class Review** | Jenna Heath | The plan presented a class review and recommendations for Cardiology medications. Major recommendations included the following:  
**Formulary Recommendations:** (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco):  
- None  
**PA Criteria Recommendations:**  
- None  
**DUR Recommendations:**  
- None  
**Committee Discussion:**  
The committee had no comments or questions. | **VOTE:**  
**Cardiology**  
Approve recommendations as presented.  
**Heart Failure & Angina Class Review**  
Motion: Ronald Ruggiero, Pharm. D  
Vote: Unanimous approval (7/7) |
| 14. **Immunology** | Kaitlin Hawkins | The plan presented a monograph and recommendations for Immunology medications. Major recommendations are listed below.  
**Formulary Recommendations:** (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO):  
- Add Takzyro™ to formulary tier 3 and require prior authorization at parity with Haegarda®  
**PA Criteria Recommendations:**  
- Update Hereditary Angioedema criteria to include Takzyro™ at parity with Haegarda® and remove | **VOTE:**  
**Immunology**  
Approve recommendations as presented with the addition to add that member can have 1 pack per month.  
**Takzyro (lanadelumab-flyo) Monograph**  
Motion: Ronald Ruggiero, Pharm. D  
Vote: Unanimous approval (7/7) |
<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
</table>
| 15. Drug Utilization Review (DUR)  
  • DUR Program Updates  
  • Prospective Program Reports (pp.132 - 142 of January 2019 P&T Packet) | Jessica Shost  
  Kaitlin Hawkins | **DUR Program Updates**  
  **Prospective Program Reports:**  
  o Top Drug Claims Data annual report  
  o Prospective DUR quarterly report Q2.2018  
  **Committee Discussion:**  
  The committee requested the Specialty cost to be added to the Pharmacy Trend Report. | Non-Voting Items |

**RECONVENE IN OPEN SESSION****

19. Summary of Closed Session  
Lisa Ghotbi  
Reconvened Open session around 9:05 am  
Non-voting item

Ralph Crowder  
The plan presented changes to the Pharmacy Policy and Procedures (P&P) for P&T committee annual review and approval:  
**Pharm-01 Pharmacy and Therapeutics Committee**  
**Document Changes:**  
- Added Healthy San Francisco to affected lines of business based on current policy  
- Clarified section III, line 10 to indicate P&T approves own minutes before QIC review  
- Updated Health Improvement to current name Health Outcomes Improvement in affected departments  
**Pharm-02 Pharmacy Prior Authorization**  
**Document Changes:**  
- Updated branding for HW and HK  
- Updated procedure statement to reflect full delegation of PA processing to PBM (effective 4/1/2019)  
- Updated Medi-Cal TAT requirements based on DHCS auditor feedback  
- Updated section 1.B, line iv to reflect full delegation  
- Updated section 2 to reflect full delegation  
- Merged sections 2.A and 2.B to describe the full review and notification process  
- Clarified language on sections 2.D and 2.E  
- Updated section 3 to reflect full delegation  
- Added section 4 to describe SFHP oversight of PBM as part of full delegation  
- Clarified language on section 5 (now section 6) to reflect continuity of care/grandfathering  

**VOTE:**  
Annual Pharmacy Policy and Procedure Review  
Approve recommendations as presented.  
**Motion:** Maria Lopez, Pharm. D.  
**Vote:** Unanimous approval (7/7)
<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>requirements and criteria based on auditor feedback</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Corrected language on section 6 (now section 7) for closed requests</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated monitoring section to reflect oversight of full delegation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated related documents to include PBM policies and procedures</td>
<td></td>
</tr>
<tr>
<td>Pharm-07: Emergency Medication Supply</td>
<td></td>
<td>Document Changes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated template for consistency</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added Healthy San Francisco to affected lines of business based on current procedure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clarified wording on applicable drug classes to be consistent based on reimplementation review</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Renamed policy for clarity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added Healthy San Francisco to affected lines of business based on current procedure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated Monitoring line 4 to reflect current procedure: Healthy Kids HMO and Healthy Workers HMO formularies are submitted to DMHC upon request</td>
<td></td>
</tr>
<tr>
<td>Pharm-13: After-Hours Pharmacy Access</td>
<td></td>
<td>Document Changes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated Care Coordination to current name Care Management in affected departments</td>
<td></td>
</tr>
<tr>
<td>Pharm-15: Generic Drug Management [new policy]</td>
<td></td>
<td>New Policy developed to address factors affecting generic utilization rate</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Committee Discussion:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The committee had no comments or questions.</td>
<td></td>
</tr>
</tbody>
</table>


Kaitlin Hawkins  

The plan presented Prior Authorization interim changes of (New Criteria, Revised Existing Criteria & a table of criteria that were evaluated per the Annual review process where no clinical changes were mad) for review and approval that will be implemented on 2/20/2019:  

Committee Discussion:  
The committee had no comments or questions.  

**VOTE:**  
**Review and Approval of Prior Authorization Criteria Interim Changes**  
Approve recommendations as presented.  

**Motion:** Maria Lopez, Pharm. D.  
**Vote:** Unanimous approval (7/7)
<table>
<thead>
<tr>
<th>Topic</th>
<th>Brought By</th>
<th>Discussion</th>
<th>Action</th>
</tr>
</thead>
</table>
| 22. Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market (pp.170 – 173 of January 2019 P&T Packet) | Kaitlin Hawkins     | The plan presented interim formulary changes and formulary status for new drugs to market. Committee Discussion: The committee had no comments or questions. | VOTE: Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market
Approve recommendations as presented. Motion: Maria Lopez, Pharm. D. Vote: Unanimous approval (7/7) |
| 23. Informational Update on New Developments in the Pharmacy Market (pp.174– 182 of January 2019 P&T Packet) | Jenna Heath         | The plan provided information on new developments in the pharmacy market. (For detail of changes, please see pages 174 - 182 of P&T packet.) | Non-voting item                                                                                 |
| 24. Adjournment                                                      | Lisa Ghotbi         | The meeting adjourned at 9:29 am. 2019 P&T Committee Meeting dates are: • Wednesday, April 17, 2019 • Wednesday, July 17, 2019 • Wednesday, October 16, 2019 | Respectfully submitted by: Lisa Ghotbi, Pharm. D. Pharmacy Director

Respectfully submitted by:

Lisa Ghotbi, Pharm. D.
Pharmacy Director

March 5, 2019

Date